Trevi Therapeutics Soars 7.53% on Anticipated Clinical Trial Results

On June 2, 2025, Trevi Therapeutics' stock surged by 7.53% in pre-market trading, driven by anticipation of significant clinical trial results and strategic corporate announcements.

Trevi Therapeutics is set to unveil the topline results from its Phase 2b CORAL trial of Haduvio, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The results, scheduled to be announced on June 2, 2025, at 8:30 a.m. ET, are expected to provide critical insights into the efficacy of Haduvio in reducing cough frequency in IPF patients.

The Phase 2b CORAL trial results are particularly noteworthy as they follow recent data indicating that Haduvio significantly reduced chronic cough in IPF patients across all doses. This positive outcome has bolstered investor confidence in the potential of Haduvio as a groundbreaking treatment for chronic cough, a condition that affects up to 85% of IPF patients and significantly impacts their quality of life.

In addition to the clinical trial results, Trevi Therapeutics has also announced a conference call and webcast to discuss the findings in detail. This event, scheduled for the same day as the results announcement, will provide investors and stakeholders with an opportunity to gain a deeper understanding of the trial outcomes and the company's future plans for Haduvio.

Trevi Therapeutics' focus on developing Haduvio as a treatment for chronic cough in IPF patients underscores the company's commitment to addressing unmet medical needs. With no approved therapies currently available for this condition, Haduvio's potential to provide significant relief to patients has generated considerable interest and optimism within the medical and investment communities.